title: Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group.
authors.forename: J
authors.initials: J
authors.lastname: Reynes
authors.forename: R
authors.initials: R
authors.lastname: Denisi
authors.forename: P
authors.initials: P
authors.lastname: Massip
authors.forename: J
authors.initials: J
authors.lastname: Izopet
authors.forename: I
authors.initials: I
authors.lastname: Pellegrin
authors.forename: M
authors.initials: M
authors.lastname: Segondy
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016049:Didanosine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D008297:Male; D010349:Patient Compliance; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D012367:RNA, Viral / Q000032:analysis; D018119:Stavudine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D018119:Stavudine; D016049:Didanosine